Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compound immunoenhancement agent, vaccine for birds and method for preparing compound immunoenhancement agent

An immune enhancer and compound technology, applied in the field of biomedicine, can solve the problems of inability to stimulate cellular immunity, short antibody maintenance time, low antibody titer, etc., to prolong the antibody duration, long antibody duration, and shorten the immune window period Effect

Active Publication Date: 2013-11-20
南京国创生物技术研究院有限公司
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

All kinds of inactivated oil emulsion vaccines with mineral oil as the delivery system stimulate the body to produce antibodies with low titers, especially for antigens with low immunogenicity similar to mycoviruses, and the antibody maintenance time is relatively short, which can hardly stimulate the body to produce effective cellular immunity

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compound immunoenhancement agent, vaccine for birds and method for preparing compound immunoenhancement agent
  • Compound immunoenhancement agent, vaccine for birds and method for preparing compound immunoenhancement agent
  • Compound immunoenhancement agent, vaccine for birds and method for preparing compound immunoenhancement agent

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] The preparation of embodiment 1 compound immunopotentiator, poultry vaccine

[0032] (1) Test material

[0033] Polymyocytes, imiquimod, resimod, muramyl dipeptide, and antiparasitic drug levamisole were purchased from SIGMA. White oil was purchased from Esso, France, and Tween-80 and Span-80 were purchased from Guangdong Zhaoqing Chaoneng Industrial Co., Ltd. Inorganic salts for preparing phosphate buffer were purchased from Sinopharm Chemical Reagent Co., Ltd.

[0034] (2) Test method

[0035] Preparation of compound immune enhancer:

[0036] Preparation of aqueous phase solution: first prepare phosphate (PBS) buffer solution, its formula contains Na 2 HPO 4 1.44g / L, KH 2 PO 4 1.44g / L for NaCl, 8g / L for NaCl, and 0.2g / L for KCl. Dissolve the above salts in double distilled water, adjust the pH to 7.0, and sterilize for later use. Then in the PBS buffer solution, add polyinosinocytes, muramyl dipeptide, levamisole, and then add Tween-80 to prepare an aqueous ...

Embodiment 2

[0053] Example 2 Effect of Compound Immunopotentiator on Immunity Efficacy and Antibody Duration of H5 Subtype Avian Influenza Vaccine

[0054] (1) Test material

[0055] Using the existing H5 subtype avian influenza vaccine, prepare H5 subtype avian influenza vaccines A, B and C containing compound immune enhancer according to the first method of Example 1. H5 subtype avian influenza vaccines A, B and C are referred to as A-VA1-Re5, B-VA1-Re5 and C-VA1-Re5 respectively. H5 subtype avian influenza vaccine and H5 subtype avian influenza standard detection antigen were purchased from Harbin Veken Biotechnology Development Company. White oil for seedling preparation was purchased from Esso, Marcol 52, France, and Tween-80 and Span-80 were purchased from Guangdong Zhaoqing Chaoneng Industrial Co., Ltd. Specific Pathogen Free (SPF) chickens purchased chicken embryos from Beijing Meria Weitong Experimental Animal Technology Co., Ltd., and were reared in isolators after self-hatchi...

Embodiment 3

[0068] The impact of embodiment 3 compound immunopotentiator on H9 subtype avian influenza vaccine immune effectiveness

[0069] (1) Test material

[0070] Using the existing H9 subtype avian influenza vaccine, prepare H9 subtype avian influenza vaccines A, B and C containing compound immune enhancer according to the first method of Example 1. The H9 subtype avian influenza vaccines A, B and C containing the compound immune enhancer are referred to as A-VA1-H9, B-VA1-H9 and C-VA1-H9 respectively. The existing H9 subtype avian influenza vaccine and H9 avian influenza detection antigen were purchased from Nanjing Tianbang Biotechnology Co., Ltd.

[0071] (2) Test method

[0072] Immunization and grouping: According to the "Compilation of Quality Standards for Biological Products for Veterinary Use (2006-2008)", referred to as "Procedures", 4-week-old chickens are immunized with 0.3mL / chicken, and chickens over 5 weeks old are immunized with 0.5mL / chicken. The immunization rout...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a compound immunoenhancement agent and an application thereof on preparing a vaccine for birds. The compound immunoenhancement agent contains 5ng-10mg / mL of poly IC, 10ng-10mg / mL of muramyl dipeptide, 10ng-5mg / mL of levamisole, 10ng-5mg / mL of resiquimod and 10ng-5mg / mL of imiquimod. After the immunoenhancement agent and H5 hypotype bird flu inactivated vaccine are mixed together, antibody can be produced one week earlier, and the antibody titer is improved above 1.8log2. After chicken are immunized through H5 hypotype bird flu inactivated vaccine, H9 hypotype bird flu vaccine or infectious bronchitis vaccine which contains the compound vaccine immunoenhancement agent, the window phases of the antibody production are shortened, the antibody titer of the vaccine is improved, the immunization duration is prolonged, and the probability of infection disease is reduced.

Description

technical field [0001] The invention relates to the field of biomedicine, in particular to a compound immune enhancer. Background technique [0002] Existing various veterinary vaccines mainly include live vaccines, inactivated vaccines and subunit vaccines. Inactivated vaccines are widely used because of their safety. Commonly used veterinary inactivated vaccines and subunit vaccines can only stimulate the body to produce humoral immunity, and it takes a long time to stimulate the body to produce antibodies. Generally, it takes 3 to 4 weeks after immunization to reach the antibody titer specified by various vaccines. During this window of lack of immune protection, there is a huge risk of epidemics. For example, it takes at least 3 weeks for the antibody titer of the routine highly pathogenic avian influenza vaccine to reach the protection standard required by my country (7log2) after immunization, and once highly pathogenic avian influenza occurs within this 3-week windo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K39/39A61K39/145A61K39/215A61P37/04A61P31/16A61P31/14
Inventor 唐应华陆吉虎吴培培杨维维李兰刘振兴田震侯继波
Owner 南京国创生物技术研究院有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products